Adra1D Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Adra1D Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ADRA1D (Alpha-1D Adrenergic Receptor) encodes the α1D-adrenergic receptor (α1D-AR), a G-protein coupled receptor that plays critical roles in smooth muscle contraction, cognitive function, and autonomic regulation. This receptor is one of three α1-adrenergic receptor subtypes (α1A, α1B, α1D) and has distinct pharmacological and physiological properties.
| Property | Value |
|---|---|
| Symbol | ADRA1D |
| Full Name | Alpha-1D Adrenergic Receptor |
| Synonyms | α1D-AR, ADRA1D |
| Chromosomal Location | 19p13 |
| NCBI Gene ID | 146 |
| OMIM ID | 104221 |
| Ensembl ID | ENSG00000160040 |
| UniProt ID | P25100 |
| Protein Length | 560 amino acids |
| Molecular Weight | ~60 kDa |
| Gene Family | Adrenergic receptor family (GPCR) |
| Inheritance | Autosomal dominant |
The ADRA1D gene is located on chromosome 19p13 and encodes a GPCR:
α1D-AR is a Gq/11-coupled receptor:
α1D-AR has widespread expression:
Highest expression in:
| Drug | Selectivity | Clinical Use |
|---|---|---|
| Terazosin | α1A/B/D | Hypertension, BPH |
| Doxazosin | α1A/B/D | Hypertension, BPH |
| Prazosin | α1A/B | Hypertension, PTSD |
| Tamsulosin | α1A > α1D | BPH (selective) |
| Silodosin | α1A > α1D | BPH (selective) |
The ADRA1D gene is located on chromosome 19q13.3 and encodes the alpha-1D adrenergic receptor. The gene spans approximately 4.5 kb and contains 2 exons. The promoter region contains response elements for various transcription factors including SP1, AP-2, and CREB.
Several single nucleotide polymorphisms (SNPs) have been identified in ADRA1D:
The α1D-AR is a G protein-coupled receptor (GPCR) with seven transmembrane domains:
| Domain | Amino Acids | Function |
|---|---|---|
| N-terminus | 1-45 | Ligand binding (extracellular) |
| TM1-7 | 46-342 | 7 transmembrane helices |
| ICL1-3 | Various | G protein coupling |
| C-terminus | 343-560 | Phosphorylation sites |
α1D-AR antagonists (tamsulosin, silodosin) are primarily used for:
ADRA1D expression in the nervous system:
Adra1D Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Adra1D Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Summers RJ, et al. (2003). "Pharmacology and functions of alpha-1 adrenergic receptor subtypes." Clin Exp Pharmacol Physiol. 30(10):731-738. PMID:12635856.
[2] Piascik MT, et al. (1995). "The alpha-1D adrenergic receptor: distribution and regulation." J Recept Signal Transduct Res. 15(1-4):267-279. PMID:8903467.
[3] Giardina WJ, et al. (1998). "Alpha-1D adrenergic receptor in memory consolidation." Prog Neuropsychopharmacol Biol Psychiatry. 22(2):293-304. PMID:9622308.
[4] Chen Y, et al. (2019). "α1-Adrenergic receptors in neurodegenerative diseases." Neurobiol Dis. 129:79-93. PMID:30978456.
[5] Scrofani R, et al. (2000). "Role of alpha1-adrenergic receptors in Alzheimer's disease." Neurobiol Aging. 21(2):263-269. PMID:10858590.
The ADRA1D gene spans approximately 3.5 kb on chromosome 20p13 and consists of 2 exons. The coding sequence is approximately 1.3 kb, encoding a 560-amino acid G-protein coupled receptor. The gene promoter contains response elements for several transcription factors including Sp1, AP-2, and CREB. Alternative splicing produces multiple transcript variants, though the functional significance of these variants in the brain remains under investigation.
ADRA1D signals primarily through Gq/11 proteins, activating phospholipase C (PLC) and leading to increased intracellular calcium. Key downstream effectors include PKC activation, MAPK signaling (ERK1/2, JNK, p38), NF-κB pathway modulation, and calcium influx through voltage-gated calcium channels. In neurons, alpha-1D signaling modulates NMDA receptor function and synaptic plasticity.
Alpha-1D receptors are therapeutic targets for several conditions. Alpha-1 blockers such as Prazosin, Terazosin, and Silodosin are used for hypertension and benign prostatic hyperplasia. In neurodegeneration, alpha-1D modulation may impact cerebral blood flow regulation, neuroinflammation modulation, and autonomic function in Parkinson's disease.
Key animal models for studying ADRA1D include knockout mice which show reduced smooth muscle contractility and altered stress responses, transgenic models with overexpression in neuronal tissues, and pharmacological models using selective agonists and antagonists.
Current research focuses on understanding ADRA1D contributions to neurodegeneration, developing brain-penetrant selective antagonists, exploring receptor dimerization and allosteric modulation, and investigating sex-specific differences in receptor function.